G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Trial watch: Monoclonal antibodies in cancer therapy
Lorenzo Galluzzi,Erika Vacchelli,Wolf Hervé Fridman,Jérôme Galon,Catherine Sautès-Fridman,Eric Tartour,Jessica Zucman-Rossi,Laurence Zitvogel,Guido Kroemer +8 more
TL;DR: This Trial Watch will review and discuss the clinical progress of the most important mAbs that are have entered clinical trials after January 2008 and some of these antibodies, which are thought to facilitate tumor eradication by initiating or sustaining a tumor-specific immune response, have already entering clinical trials.
Journal ArticleDOI
Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from “Silent” to Immunogenic
Michel Obeid,Michel Obeid,Theocharis Panaretakis,Antoine Tesniere,Antoine Tesniere,N Joza,N Joza,Roberta Tufi,Roberta Tufi,Lionel Apetoh,François Ghiringhelli,Laurence Zitvogel,Guido Kroemer,Guido Kroemer +13 more
TL;DR: It is shown that calreticulin exposure was necessary and sufficient to increase proimmunogenic killing by other chemotherapies, and that tactics to expose cal reticulin might improve the clinical efficacy of many cancer therapies.
Journal ArticleDOI
Higher spermidine intake is linked to lower mortality: a prospective population-based study.
Stefan Kiechl,Raimund Pechlaner,Raimund Pechlaner,Peter Willeit,Peter Willeit,Peter Willeit,Marlene Notdurfter,Bernhard Paulweber,Karin Willeit,Philipp Werner,Christoph Ruckenstuhl,Bernhard Iglseder,Siegfried Weger,Barbara Mairhofer,Markus Gartner,Ludmilla Kedenko,Monika Chmelíková,Slaven Stekovic,Hermann Stuppner,Friedrich Oberhollenzer,Guido Kroemer,Manuel Mayr,Tobias Eisenberg,Herbert Tilg,Frank Madeo,Johann Willeit +25 more
TL;DR: The association between spermidine content in diet and mortality in humans was consistent in subgroups, robust against unmeasured confounding, and independently validated in the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk Study.
Journal ArticleDOI
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani,Dalil Hannani,Dalil Hannani,Marie Vétizou,Marie Vétizou,Marie Vétizou,David Enot,David Enot,Sylvie Rusakiewicz,Sylvie Rusakiewicz,Nathalie Chaput,Nathalie Chaput,David Klatzmann,Mélanie Desbois,Mélanie Desbois,Nicolas Jacquelot,Nicolas Jacquelot,Nicolas Jacquelot,Nadege Vimond,Nadege Vimond,Salem Chouaib,Christine Mateus,James P. Allison,Antoni Ribas,Jedd D. Wolchok,Jianda Yuan,Philip C. Wong,Michael A. Postow,Andrzej Mackiewicz,Jacek Mackiewicz,Dirk Schadendorff,Dirk Jaeger,Alan J. Korman,Keith S. Bahjat,Michele Maio,Luana Calabrò,Michele W.L. Teng,Michele W.L. Teng,Mark J. Smyth,Mark J. Smyth,Alexander M.M. Eggermont,Alexander M.M. Eggermont,Caroline Robert,Guido Kroemer,Laurence Zitvogel +44 more
TL;DR: This study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma.
Journal ArticleDOI
Illicit survival of cancer cells during polyploidization and depolyploidization
Ilio Vitale,Lorenzo Galluzzi,Lorenzo Galluzzi,Lorenzo Galluzzi,Laura Senovilla,Laura Senovilla,Laura Senovilla,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Mohamed Jemaà,Mohamed Jemaà,Mohamed Jemaà,Maria Castedo,Maria Castedo,Maria Castedo,Guido Kroemer +16 more
TL;DR: It is speculated that the identification of signaling/metabolic cascades that are required for the survival of tetraploid or aneuploid (but not diploid) cancer cells may pave the way for the development of novel broad-spectrum anticancer agents.